. DTIC and CA inhibited the growth of A375 tumor xenografts. (A) In the preliminary test, A375 cells were subcutaneously injected into the upper left flank region of nude mice. When the tumors had formed for one week, CA (15, 30 or 60 mg/kg/day) was treated for one week. (B) A375 cells were subcutaneously injected into the upper left flank region of nude mice. When the tumors had formed for one week, mice were treated with DTIC (25, 50 or 100 mg/kg/day) and CA (15, 30 or 60 mg/kg/day) for two weeks. PBS was used as a negative control. Finally, mice were sacrificed by decollement, and tumor tissues were stripped. (n = 6, expressed as means ± standard deviation). Figure 2B was recovered from the gel and sent for HPLC-mass spectrometry identification. The main peptide fragments identified by protein mass spectrometry were listed. (D) Sequence alignment analysis for ENO1 protein in human and mouse. The underlined portion is the differential amino acid. The red color represents the sequence fragment that was identified by protein mass spectrometry. Figure S5 . CA colocalized with ENO1 both in vitro (A) and in vivo (B). The pseudo red color represents ENO1, which was stained by Alexa Fluor 594, and the Al-CA probe took on a pseudo green color via the click reaction. The statistical result of fluorescence sensitivity was used Image J software to analyze and it was showed a high overlapping (>90%) at the underline position (blue), which was in Figure S10. Cells were treated with 6.25 or 12.5 μM DTIC and with 0 or 10 μM CA for 24 h and were analyzed with a flow cytometry system, and the G2M or S phase ratio to G0/G1 was calculated, respectively. Figure S11 . A375 cells were treated with 0, 5, 10, 20, 40 or 80 μM CA for 24 h, and the related protein were detected by Western blotting. Results showed that after CA treatment, the phosphorylation (P-) of JNK was decreased at high concentration (>40 μM), and the change of P-ERK1/2 and P-P38 were not evident in the downstream of Pi3K/Akt pathway. The expression of Glut1 was observably suppressed by CA (>10 μM).
Part Two
In this section, we have provided all the original blots. Each experiment was repeated three times. We have marked the molecular weight markers on the Western blotting images in the final figures of the manuscript.
The molecular weight marker that we have used in the current study was purchased from Thermo Fisher Scientific (Cat. 26616/26619, Shanghai, China) . We have used the Chemiluminescence imaging system (Cat. Tanon-5200, Shanghai, China). Image software was used for all sensitivity analyses, and we adopt the relative quantitative statistics and normalized the value. Figure 2C . Image software was used for sensitivity analysis, and the relative quantitative statistics and normalized the intensity value against 37ºC were adopted. Western blotting was performed 3 times. The "Repeat 2" was used in Figure 2C of the manuscript. Figure S14 . Original unedited bands for evaluating CA treatment decreased the thermal stability of ENO1 in cell lysates measured by the concentration-dependent CETSA at 69 °C in Figure 2D . In order to unify the number of strips in Figure 2C , the first strip (0 μM) was cut off in this figure as it corresponds to a negative control. Image software was used for sensitivity analysis, and the relative quantitative statistics and normalized the intensity value against CA unadded control group (0 μM) were adopted. Western blotting was performed 3 times. The "Repeat 1" was used in Figure 2D of the manuscript. Figure S15 . Original unedited bands for evaluating CA inhibited ENO1 function in Figure 4D . A375 cells were transfected with siENO1 for 48 h, and the expression of ENO1 in cells was assayed by Western blotting 3 times. Image software was used for sensitivity analysis, and the relative quantitative statistics and normalized the density value of the control group were adopted. The "Repeat 3" was used in Figure 4D of the manuscript.
